MA
RPRX icon

Montag & Associates’s Royalty Pharma RPRX Stock Holding History

Montag & Associates’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-33
Closed -$871 – 1046
2024
Q2 		$871 Hold
33
– – ﹤0.01% 948
2024
Q1 		$1K Hold
33
– – ﹤0.01% 926
2023
Q4 		$927 Hold
33
– – ﹤0.01% 886
2023
Q3 		$896 Hold
33
– – ﹤0.01% 874
2023
Q2 		$1.01K Sell
33
-5
-13% -$169 ﹤0.01% 890
2023
Q1 		$1.37K Hold
38
– – ﹤0.01% 878
2022
Q4 		$1.5K Buy
+38
New +$1.59K ﹤0.01% 882

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Montag & Associates's RPRX Position: Q3 2024 in Review

Montag & Associates sold out of Royalty Pharma (RPRX) in Q3 2024, closing a stake of 33 shares — an estimated $871 sold.

Montag & Associates first reported a position in RPRX in Q4 2022 and held it in 7 quarters. The position peaked at $1.5K in Q4 2022. 395 funds tracked by Wall St. Rank hold RPRX as of Q3 2024.

  • Montag & Associates reported no remaining Royalty Pharma position as of Q3 2024 after selling out during the quarter.
  • Montag & Associates sold 33 Royalty Pharma shares in Q3 2024, an estimated $871.
  • Montag & Associates first reported a position in Royalty Pharma in Q4 2022 and held it in 7 quarters.
  • Montag & Associates's Royalty Pharma position peaked at $1.5K in Q4 2022.
  • 395 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2024.

Based on Montag & Associates's 13F filing for Q3 2024, filed 5 Nov 2024.